Navigation Links
2-step immunotherapy attacks advanced ovarian cancer
Date:1/31/2013

PHILADELPHIA -- Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment a dendritic cell vaccine using patients' own tumor followed by adoptive T cell therapy triggers anti-tumor immune responses in these type of patients. Four of the six patients treated in the trial responded to the therapy, the investigators report this month in OncoImmunology.

"What we proved in this study is that this is a safe treatment strategy," says co-first author Lana Kandalaft, PharmD, MTR, PhD, research assistant professor of Obstetrics and Gynecology and director of clinical development in the Ovarian Cancer Research Center. "It is a walk in the park for patients, especially compared to standard chemotherapies and surgical treatments for ovarian cancer literally, some patients left the clinic and went for a walk in a nearby park after their treatment."

The findings follow research by the study's senior author, George Coukos, MD, PhD, director of the Ovarian Cancer Research Center at Penn, who showed in 2003 that women whose ovarian tumors were infiltrated by healthy immune cells, called T cells, tended to live longer than women whose tumors were devoid of T cells. That observation and other subsequent ones suggest the patient's immune system is trying to fight off the disease but can't quite muster the strength to beat it. Therefore, investigators have been trying to find ways using patients' own tumor cells to boost the immune system's power.

In the current study, Coukos, Kandalaft, co-first author Daniel J. Powell Jr., PhD, research assistant professor of Pathology and Laboratory Medicine, and colleagues treated six women with advanced ovarian cancer in a two-staged immunotherapy protocol in which they utilized a d
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. 12-Step Meetings May Help Teens Beat Alcohol, Drug Abuse
2. Immunotherapy reduces allergic patients sensitivity to peanuts
3. Sublingual immunotherapy shows promise as treatment for peanut allergy
4. Moffitt researchers say effective immunotherapy for melanoma hinges on blocking suppressive factors
5. Antibodies reverse type 1 diabetes in new immunotherapy study
6. Immunotherapy for elderly cancer patients finds new promise in drug combination
7. Toward a better cyanide antidote for terrorist attacks and other mass casualty events
8. New Guidelines Seek to Streamline Care for Worst Heart Attacks
9. Penn research reveals new aspect of platelet behavior in heart attacks: Clots can sense blood flow
10. Study Tallies Economic Fallout From Workers Heart Attacks
11. Decline in incidence of heart attacks appears associated with smoke-free workplace laws
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... Monroeville, PA (PRWEB) March 02, 2015 ... part of the Allegheny Health Network, are ... with new software called Visual Info Zonal Reminder (VIZR), ... , Introduced in 2013, Google Glass is a wearable ... in a smartphone-like hands-free format. Wearers communicate with the ...
(Date:3/2/2015)... CA (PRWEB) March 02, 2015 Ticket ... tickets at the Hollywood Bowl . This popular site ... customer appreciation promo code JIMMY-BUFFETT-2015 for added savings. , ... their favorite performer will be headlining at the Hollywood ... concert will be on Thursday, October 22nd and it ...
(Date:3/2/2015)... 02, 2015 Doctors in Novara, Italy ... better predictor of outcomes for people with mesothelioma than ... of the new study on the Surviving Mesothelioma ... University of Eastern Piedmont followed the cases of 172 ... for excess lung fluid. , “Persistent lung expansion ...
(Date:3/2/2015)... 02, 2015 Burns Engineering's Lab-to-Lab ... for Secondary Standard Platinum Resistance Thermometers (SSPRTs) and ... days or less . . . guaranteed. ... Accredited (Lab Code 200706-0), ISO 9001 and 17025 ... range is -196°C to 500°C, both ITS-90 and ...
(Date:3/2/2015)... The minimally invasive surgical instruments market ... 6.1% to reach $14,133.0 million by 2019 from ... as advantages of minimally invasive surgeries over traditional ... invasive surgeries and increasing number of surgical procedures ... minimally invasive surgical instruments market. , For More ...
Breaking Medicine News(10 mins):Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 2Health News:Pennsylvania Hospital Explores Use of Google Glass for Trauma Care 3Health News:Cheap Jimmy Buffett Tickets Hollywood Bowl: Ticket Down Slashes Prices on Jimmy Buffett Tickets at the Hollywood Bowl in Los Angeles/Hollywood, CA 2Health News:New Research Links Talc Treatment Response with Mesothelioma Prognosis, According to Surviving Mesothelioma 2Health News:Burns Engineering Announces Quick-Turn Temperature Calibrations 2Health News:Minimally Invasive Surgical Instrument Market - Global Forecast to 2019 - New Report by MarketsandMarkets 2
... University may have isolated the substance most responsible// for ... a discovery that could revolututionise treatments for a host ... by Riyi Shi (REE-yee SHEE) has found that a ... high levels in spinal tissue for several days after ...
... who are being diagnosed for diabetes type 2 may ... the onset of the disease. ,A study done ... have shown that among the children who are newly ... five of them have showed tendencies of being afflicted ...
... to find out why the diabetes drug thiazolidinediones (TZDs) can ... found that the drug TZDs activates a receptor in kidney ... the collecting duct of the kidney. The activation of the ... causes edema. ,TZD drugs are generally used to lower ...
... the help of anti fungal medication itraconazole can reduce ... have broken new grounds in asthma treatment by using ... aspergillosis, which is a form of asthma. , ... with steroids or drugs that have equally disastrous side ...
... is trying new approaches to the neuroblastoma patients, researchers// ... more effective in children than the common procedure. ... that the cancer drug topotecancan must be fine tuned ... all doses are effective on everybody. Only less than ...
... placebo treatment can reduce the nature of emotional experience// ... treatment consists of dummy medication or intervention. This can ... injections etc. ,In the new research done by ... placebo treatment can effectively control the impact of negative ...
Cached Medicine News:Health News:Acrolein may be the key to halting spinal cord damage 2Health News:Acrolein may be the key to halting spinal cord damage 3Health News:Acrolein may be the key to halting spinal cord damage 4
(Date:3/2/2015)... , March 2, 2015 Nevro Corp. (NYSE: ... has developed and commercialized an innovative, evidence-based neuromodulation platform ... Brad Vale , PhD, DVM, former Head of ... to its Board of Directors, effective March 1, 2015. ... of experience in developing, commercializing and investing in innovative ...
(Date:3/2/2015)... WEST JORDAN, Utah , March 2, 2015 ... of Medical Imaging Solutions, has acquired Eclipse Systems, ... and customized service solutions. As part of their ... comprehensive service at an affordable rate, BC Technical ... strategic acquisition allows BC Technical to add valuable ...
(Date:3/2/2015)... 2, 2015  DURECT Corporation (Nasdaq: ... and the successful completion of a Phase 1 ... DUR-928.  DUR-928 is an endogenous, small-molecule, new chemical ... metabolic diseases such as nonalcoholic fatty liver disease ... organ injuries such as acute kidney injury (AKI).  ...
Breaking Medicine Technology:Nevro Appoints Dr. Brad Vale to its Board of Directors 2BC Technical Acquires Eclipse Systems 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 2DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 3DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 4DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development 5
... Dec. 9, 2010 The national media keeps ringing the ... the NYU one-year research study on pediatric dosing instructions on ... the American Medical Association ,s December issue. The results are ... liquid medications, found inconsistencies across all the medications, with the ...
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), a ... with inflammation, today announced it will hold a conference ... and remediation plans relating to vial problems in the ... 2010Time: , 5:00 pm Eastern TimeDomestic Dial-in: , (877) ...
Cached Medicine Technology:AccuDial® Pharmaceutical Solves OTC Dosing Errors for Children's Liquid Medications 2AccuDial® Pharmaceutical Solves OTC Dosing Errors for Children's Liquid Medications 3Anthera Announces Update Call Regarding Vial Problems 2
Designed specifically for use with children ages,3 and up The patient is asked to distinguish between a "Raised E" and a non stereo target....
... The Standard for Stereo Depth ... to 1200 sec or arc) and ... Graded Circle Test (800 to 40 ... Children (400 to 100 sec of ...
... Emit 2000 Phenytoin Assay is ... for use in the quantitative ... serum or plasma. Kits are ... the Roche COBAS MIRA, COBAS ...
... The Emit 2000 Digoxin Assay ... intended for use in the ... human serum or plasma. Kits ... on the Roche COBAS MIRA, ...
Medicine Products: